{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T23:10:05Z","timestamp":1733958605756,"version":"3.30.2"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1038\/s41571-022-00670-w","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T12:02:59Z","timestamp":1659960179000},"page":"617-618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["When an embarrassment of riches isn\u2019t enough"],"prefix":"10.1038","volume":"19","author":[{"given":"Krina","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"670_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"670_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"670_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478","author":"P Moreau","year":"2022","unstructured":"Moreau, P. et al. Teclistamab in elapsed or refractory multiple myeloma. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2203478 (2022).","journal-title":"N. Engl. J. Med."},{"key":"670_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21, 207\u2013222 (2020).","journal-title":"Lancet Oncol."},{"key":"670_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari, A. et al. Oral selinexor-dexamethasone for triple-class efractory multiple myeloma. N. Engl. J. Med. 381, 727\u2013738 (2019).","journal-title":"N. Engl. J. Med."},{"key":"670_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur, M. K. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat. Commun. 12, 868 (2021).","journal-title":"Nat. Commun."},{"key":"670_CR7","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Vi\u00e0","year":"2021","unstructured":"Da Vi\u00e0, M. C. et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat. Med. 27, 616\u2013619 (2021).","journal-title":"Nat. Med."},{"issue":"suppl.","key":"670_CR8","doi-asserted-by":"publisher","first-page":"8006","DOI":"10.1200\/JCO.2022.40.16_suppl.8006","volume":"16","author":"AM Lesokhin","year":"2022","unstructured":"Lesokhin, A. M. et al. Initial safety results for MagnetisMM-3: a phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed\/refractory (R\/R) multiple myeloma (MM). J. Clin. Oncol. 16 (suppl.), 8006 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"670_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2021-147983","volume":"138","author":"S Trudel","year":"2021","unstructured":"Trudel, S. et al. Cevostamab monotherapy continues to show clinically meaningful activity and anageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study. Blood 138 (Suppl. 1), 157 (2021).","journal-title":"Blood"},{"issue":"suppl. 15","key":"670_CR10","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1200\/JCO.2021.39.15_suppl.8008","volume":"39","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)\u2009\u00d7\u2009CD3 bispecific antibody, in relapsed\/refractory multiple myeloma (MM). J. Clin. Oncol. 39 (suppl. 15), 8008 (2021).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00670-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00670-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00670-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T22:51:42Z","timestamp":1733957502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00670-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["670"],"URL":"https:\/\/doi.org\/10.1038\/s41571-022-00670-w","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"type":"print","value":"1759-4774"},{"type":"electronic","value":"1759-4782"}],"subject":[],"published":{"date-parts":[[2022,8,8]]},"assertion":[{"value":"8 August 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.P. has acted as a consultant for Arcellx, BMS, Caribou Biosciences, Celgene, Cellectis, Janssen, Karyopharm, Legend Biotech, Merck, Nektar, Pfizer, Takeda. S.L. has acted as a consultant for ABBVIE, Amgen, BMS, Celgene, GSK, Janssen, Novartis, Takeda, is a member of the board of directors and holds stock in TG therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}